NCT04221932 (QUALITY-CRRT) is a clinical trial of CRRT KPI Reports in Critical Illness, sponsored by University of Alberta.

Who is sponsoring NCT04221932?

NCT04221932 is sponsored by University of Alberta.

What drugs are being tested in NCT04221932?

Interventions in NCT04221932: CRRT KPI Reports.

What condition does NCT04221932 study?

NCT04221932 studies Critical Illness, Acute Kidney Failure.

Is NCT04221932 still recruiting?

NCT04221932 is currently completed. Last updated 30 March 2025.

Last reviewed 2025-03-30 · How we verify

NCT04221932: QUALITY-CRRT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Implementation of CRRT KPI Reports to Standardize and Improve the Quality of CRRT Delivery in Alberta "QUALITY CRRT"

Completed Last updated 30 March 2025

What this trial tests

trial testing CRRT KPI Reports in Critical Illness in 945 participants. Completed in 31 December 2024.

Timeline

5 July 2022

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	University of Alberta
Status	Completed
Study type	OBSERVATIONAL
Enrollment	945
Start date	5 July 2022
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	14 locations across Canada

Drugs / interventions tested

CRRT KPI Reports

Conditions studied

Critical Illness — all drugs for Critical Illness →
Acute Kidney Failure — all drugs for Acute Kidney Failure →

Sponsor

University of Alberta

Who can join

1 and older, any sex, with Critical Illness or Acute Kidney Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute kidney replacement therapy (i.e., dialysis) is used in 6-10% of patients admitted to intensive care units (ICUs). The amount of acute kidney replacement therapy use has increased in Canadian ICUs over the last several years. Continuous renal replacement therapy (CRRT) remains the most common form of acute renal replacement therapy used in ICUs. Many different parts aspects of CRRT lack a usual way to be done, and because of this, are done differently in different ICUs. Not having generally accepted markers of the performance and delivery of CRRT is a main reason that we have these practice difference. This is an important gap in the way that clinicians deliver this important ICU therapy and is a main focus of ongoing research in ICU and dialysis. The proposed project is a continuation of a program of work that first reviewed the current state of the quality and safety in ICU and dialysis. Then, a systematic review of all potential quality markers was done to see what options for measures were possible. Next, following a meeting of leaders of dialysis in the ICU, the most important of these measures were ranked to decide which ones could be used in monitoring CRRT for patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Improving the quality of the performance and delivery of continuous renal replacement therapy (CRRT) to critically ill patients across a healthcare system: QUALITY CRRT: a study protocol.
Opgenorth D, Reil E, Lau V, Fraser N, et al · · 2022 · cited 10× · PMID 35121604 · DOI 10.1136/bmjopen-2021-054583

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting

Other University of Alberta trials

Trials by the same sponsor.

NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04221932 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alberta
Last refreshed: 30 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04221932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing